NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
Fate Therapeutics
ADC Therapeutics S.A.
Stanford University
Hackensack Meridian Health
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
GlaxoSmithKline